Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
BMC Cardiovasc Disord ; 20(1): 165, 2020 04 09.
Artigo em Inglês | MEDLINE | ID: mdl-32272880

RESUMO

BACKGROUND: Long term ß-blocker therapy after myocardial infarction (MI) reduces mortality and recurrent MI but evidence for this treatment predates contemporary acute coronary care. ß-blocker treatment is a key quality of care indicator in the Swedish national quality register for acute coronary care, Riks-HIA. Between 2011 and 2015 a declining number of MI-patients discharged with a ß-blocker from the coronary care unit (CCU) at Helsingborg and other hospitals was reported. This retrospective observational study aimed to investigate the causes for discharge without a ß-blocker and relate it to outcome, compared to patients discharged with a ß-blocker. METHODS: MI-patients registered in Riks-HIA discharged without ß-blocker during 2011-2015 (no-ß-group) and a control group (ß-group) comprised of patients discharged with ß-blocker treatment between January 1 to December 31, 2013, were matched by RIKS-HIA criteria for ß-blocker use. Clinical characteristics, date of death, readmission for MI, other cardiovascular events were collected from Riks-HIA and medical records. RESULTS: The no-ß-group included 141 patients, where 65.2% had a justified reason for non-ß-blocker use. The ß-group included 206 patients. There was no difference in cardiovascular risk factor profile. There were a trend towards a higher number of readmissions for MI in the no-ß-group was (n = 8 (5.7%) vs n = 2 (1.0%), p = 0.02), but not mortality (6 (4.3%) vs 2 (1.0%), p = 0.07) and combined readmission for angina pectoris, heart failure, arrhythmias or stroke/TIA (n = 23 (16.3%) vs n = 25 (12.1%), p = 0.27). CONCLUSION: A majority of the patients in the no-ß-group had a justified absence of a ß-blocker. ß-blocker treatment post-MI showed a trend towards fewer readmissions for MI. But important quality information is lacking to make a firm conclusion of the effect on outcome.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Prevenção Secundária , Antagonistas Adrenérgicos beta/efeitos adversos , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/mortalidade , Revascularização Miocárdica , Alta do Paciente , Readmissão do Paciente , Recidiva , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Suécia , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA